Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials

Langley Richard G. B.; Cohen Arnon D.; Foley Peter; Griffiths Christopher E. M.; Lebwohls Mark; Leonardi Craig; Winthrop Kevin; Proulx James; Rottinghaus Scott T.; Wolk Robert; Thompson John R.; Tatulych Svitlana; Mallbris Lotus; Swanson Robert

首页> 外文期刊>The Journal of investigative dermatology. >Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials

【24h】

Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials

机译：口服Janus激酶抑制剂Tofacitinib在治疗慢性斑块状牛皮癣中的安全性：来自全球临床试验的综合数据分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Journal of investigative dermatology.》 |2015年第3期|共1页
作者
Langley Richard G. B.; Cohen Arnon D.; Foley Peter; Griffiths Christopher E. M.; Lebwohls Mark; Leonardi Craig; Winthrop Kevin; Proulx James; Rottinghaus Scott T.; Wolk Robert; Thompson John R.; Tatulych Svitlana; Mallbris Lotus; Swanson Robert;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献
中文文献
专利

1. Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials [J] . Langley Richard G. B., Cohen Arnon D., Foley Peter, The Journal of investigative dermatology. . 2015,第Suppla3期

机译：口服Janus激酶抑制剂Tofacitinib在治疗慢性斑块状牛皮癣中的安全性：来自全球临床试验的综合数据分析
2. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study [J] . Papp Kim A., Krueger James G., Feldman Steven R., Journal of the American Academy of Dermatology . 2016,第5期

机译：口服Janus激酶抑制剂Tofacitinib用于治疗慢性斑块状牛皮癣：2项随机III期研究和1项开放标签长期延伸研究的长期疗效和安全性结果
3. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials [J] . Papp K. A., Menter M. A., Abe M., British Journal of Dermatology . 2015,第4期

机译：口服Janus激酶抑制剂Tofacitinib用于治疗慢性斑块状牛皮癣：两项随机，安慰剂对照的III期临床试验的结果
4. Proteomics-based target deconvolution of clinical multi-kinase inhibitors inducing apoptosis in primary chronic lymphocytic leukemia cells (CLL) [C] . Marcus Bantscheff, Ulrich Kruse, Christian P. Pallasch, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：基于蛋白质组学的临床多激酶抑制剂诱导肾凋亡凋亡的靶碎屑（CLL）
5. Analysis of data from a clinical trial comparing different drug treatments for dyspepsia using binomial regression and binary classification trees [D] . Rose, Caren 2004

机译：使用二项式回归和二叉分类树比较一项针对消化不良的不同药物治疗的临床试验数据进行的分析
6. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis [O] . WC Ports, S Khan, S Lan, -1

机译：局部Janus激酶抑制剂托法替尼治疗慢性斑块状牛皮癣的随机2a期疗效和安全性试验
7. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study [O] . Papp Kim A., Krueger James G., Feldman Steven R., 2016

机译：口服Janus激酶抑制剂Tofacitinib用于治疗慢性斑块状牛皮癣：2项随机III期研究和1项开放标签长期延伸研究的长期疗效和安全性结果

Safety of tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: integrated data analysis from the global clinical trials

著录项

相似文献

相关主题

期刊订阅